On April 27, 2018 Innate Pharma reported that it presented new data at the AACR (Free AACR Whitepaper) Annual Meeting, April 14-18, in Chicago, including preliminary data suggesting promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN (Press release, Innate Pharma, APR 27, 2018, View Source [SID1234525774]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!